ZEN-012
ZEN-012 Uses, Dosage, Side Effects, Food Interaction and all others data.
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
In vitro: ZEN-012 has shown potent in vitro anti-proliferative activity at nanomolar concentrations against human tumor cell lines of different origin. ZEN-012 is active in tumor cell lines which are resistant to cisplatin and doxorubicin as well as to tubulin inhibitors such as vincristine and paclitaxel. Furthermore, it was shown thatZEN-012 is a catalytic inhibitor of the enzyme topoisomerase II with the same potency as amsacrine.
In vivo: Given orally once or twice weekly, ZEN-012 proved to be a potent inhibitor of in vivo tumor growth in mammary, lung, renal, colon, melanoma xenograft models as well as in leukemia cancer models at well tolerated doses (16-40mg/kg). Furthermore,ZEN-012 showed good safety and toxicity profiles in a series of rodent and non-rodent studies.
| Trade Name | ZEN-012 |
| Generic | ZEN-012 |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Investigated for use/treatment in cancer/tumors (unspecified).
How ZEN-012 works
Mode of action studies revealed that the compound ZEN-012 inhibits the polymerization of ß-tubulin in low micromolar concentrations. Competition studies suggest that ZEN-012 interacts with the same binding site on microtubules as colchicine. ZEN-012 destroys the mitotic spindles of the cancer cells, arrests the cancer cells in G2/M phase at low concentrations, mediates DNA fragmentation via inhibition of topoisomerase II and induces apoptosis via various mechanisms.
Innovators Monograph
You find simplified version here ZEN-012
